Hillsdale Investment Management Inc. Takes $108,000 Position in Theratechnologies Inc. (NASDAQ:THTX)

Hillsdale Investment Management Inc. bought a new position in shares of Theratechnologies Inc. (NASDAQ:THTX) during the fourth quarter, HoldingsChannel.com reports. The firm bought 59,578 shares of the company’s stock, valued at approximately $108,000.

Several other institutional investors and hedge funds also recently modified their holdings of THTX. National Bank of Canada FI increased its stake in Theratechnologies by 29.4% in the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after purchasing an additional 42,435 shares during the last quarter. Virtu Financial LLC purchased a new position in Theratechnologies in the 4th quarter worth approximately $40,000. Wealthspire Advisors LLC grew its holdings in Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after purchasing an additional 20,000 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Theratechnologies during the 4th quarter valued at approximately $27,000. Finally, Harbour Investments Inc. increased its stake in shares of Theratechnologies by 20.0% in the fourth quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock worth $159,000 after buying an additional 14,655 shares during the last quarter.

Theratechnologies Stock Performance

THTX opened at $1.57 on Tuesday. Theratechnologies Inc. has a one year low of $1.08 and a one year high of $2.18. The company has a market capitalization of $72.19 million, a PE ratio of -15.70 and a beta of 1.24. The stock’s fifty day moving average is $1.65 and its 200-day moving average is $1.48.

Wall Street Analysts Forecast Growth

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.